BenevolentAI
VerifiedBenevolentAI is a leading, clinical-stage AI-enabled drug discovery company.
Launch date
Employees
Market cap
-
Net debt
-
Enterprise valuation
$50m (Public information from Jul 2024)
Share price
€0.65 BAI.AS
Company register number 09781806
London England (HQ)
| GBP | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 | 2026 |
|---|---|---|---|---|---|---|---|
| Revenues | 0000 | 0000 | 0000 | 0000 | 0000 | 0000 | 0000 |
| % growth | 49 % | (33 %) | 128 % | (31 %) | - | - | (41 %) |
| EBITDA | 0000 | 0000 | 0000 | 0000 | 0000 | 0000 | 0000 |
| % EBITDA margin | (900 %) | (1806 %) | (1823 %) | (953 %) | - | (86 %) | (186 %) |
| Profit | 0000 | 0000 | 0000 | 0000 | 0000 | 0000 | 0000 |
| % profit margin | (802 %) | (1870 %) | (1552 %) | (864 %) | - | (51 %) | (124 %) |
| EV / revenue | 00.0x | 00.0x | 00.0x | 00.0x | 00.0x | 00.0x | 00.0x |
| EV / EBITDA | 00.0x | 00.0x | 00.0x | 00.0x | 00.0x | 00.0x | 00.0x |
| R&D budget | 0000 | 0000 | 0000 | 0000 | 0000 | 0000 | 0000 |
| R&D % of revenue | 1049 % | 1018 % | 616 % | 829 % | - | - | - |
Source: Dealroom estimates
Get premium to view all results
| Date | Investors | Amount | Round |
|---|---|---|---|
| investor investor investor | $0.0 Valuation: $0.0 | round | |
| investor investor | $0.0 Valuation: $0.0 268.8x EV/LTM Revenues | round | |
| investor | $0.0 Valuation: $0.0 111.0x EV/LTM Revenues | round | |
| investor | $0.0 | round | |
| investor | $0.0 Valuation: $0.0 181.0x EV/LTM Revenues -20.1x EV/LTM EBITDA | round | |
* | €135m Valuation: €1.5b 181.0x EV/LTM Revenues -20.1x EV/LTM EBITDA | SPAC Private Placement | |
| Total Funding | 000k | ||
Related Content
Recent News about BenevolentAI
EditTech stack
Tech stackLearn more about the technologies and tools that this company uses.